07:47 Mon 21 Oct 2019
ValiRx PLC - Passing of Non-Executive Chairman
("
Passing of Non-Executive Chairman
The Board offers its deepest sympathies to Oliver's wife and family. Dr Satu Vanikka,
*** ENDS ***
For more information, please contact:
|
Tel: +44 (0) 20 3008 4416 |
Dr |
Tel: +44 (0) 20 3008 4416 |
|
Tel: +44 (0) 7879 458 364 |
|
|
|
Tel: +44 (0) 20 7213 0880 |
|
|
|
Tel: +44 (0) 20 7399 9400 |
Notes for Editors
About
The Company's business model focuses on out-licensing therapeutic candidates early in the development process. By aiming for early-stage value creation, the company reduces risk considerably while increasing the potential for realising value. The group is already in licensing discussions with major players in the oncology field.
Until recently, cancer treatments relied on non-specific agents, such as chemotherapy. With the development of target-based agents, primed to attack cancer cells only, less toxic and more effective treatments are now possible. New drugs in this group-such as those in
The Company listed on the AIM Market of the
This information is provided by RNS, the news service of the
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of...
FOR OUR FULL DISCLAIMER CLICK HERE